Trial Profile

A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amcasertib (Primary)
Indications Carcinoma; Renal cell carcinoma; Urogenital cancer
Focus Therapeutic Use
Sponsors Boston Biomedical; Sumitomo Pharma Oncology

Most Recent Events

07 Jul 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to Low feasibility.
13 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2018.
13 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Jan 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com